📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. (2014)

First Author: Backen A

Attributed to: Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-13-3248

PubMed Identifier: 24947924

Publication URI: http://europepmc.org/abstract/MED/24947924

Type: Journal Article/Review

Volume: 20

Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research

Issue: 17

ISSN: 1078-0432